MedTrace Logo

Antidepressant Safety in Kids Study

NCT00395213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 569

Last updated 2015-04-17

No results posted yet for this study

Summary

This study will evaluate the risks and benefits of treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder.

Conditions

  • Anxiety Disorders
  • Depressive Disorders
  • Eating Disorders
  • Obsessive Compulsive Disorder

Interventions

DRUG

Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications

Treatment with SSRIs or SNRIs

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • John S. March, MD, MPH · Duke University

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395213 on ClinicalTrials.gov